By Katherine Hamilton
Kamada shares climbed after the company released its guidance for 2025 and updated its progress on a therapy trial.
The biopharmaceutical company's stock advanced 16% to $7.92. Shares have gained 30% over the past 12 months.
Kamada expects to earn $178 million to $182 million in revenue during 2025, which would be a 13% increase from the previous year. It anticipates $38 million to $42 million in adjusted EBITDA.
The company affirmed guidance for $158 million to $162 million in annual revenue in 2024. Year-end cash should be around $78 million, it said. Adjusted EBITDA is anticipated to be $32 million to $35 million.
The operational cash will provide resources for new business development and mergers and acquisitions in 2025, Chief Executive Amir London said. Kamada also plans to expand its plasma collection operations, including opening a third location in San Antonio in the first quarter of 2025.
Kamada expects to advance its phase-three trial of its Inhaled Alpha-1 Antitrypsin therapy. The FDA confirmed an agreement for the trial, which will allow Kamada to reduce the study sample size from 220 patients to 180 while maintaining statistical power. An interim futility analysis is expected to happen by the end of 2025.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
January 08, 2025 14:06 ET (19:06 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。